I am a healthcare professional in the UK
I am a patient or member of the publicPost-Transplant
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
You might be interested in
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
